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 Introduction 
 Mastocytosis is an extremely heterogeneous disorder 
of bone marrow origin ranging from self-limiting cuta-
neous diseases in the childhood to aggressive or leuke-
mic systemic disorders with fatal course in the adult
( table  1 ). Systemic mastocytosis (SM) is defined as
histologically proven involvement of at least one extra-
cutaneous tissue and is usually diagnosed in the bone 
marrow. Histological investigation including immuno-
histochemical stainings with antibodies against three 
important mast cell-related antigens, namely tryptase, 
CD117 ( KIT ) and CD25, allows a diagnosis of mastocy-
tosis to be established or excluded in almost all cases  [1] . 
While coexpression of tryptase and CD117 defines the 
normal phenotype of mast cells present in all reactive 
and neoplastic states, expression of CD25 is seen almost 
exclusively in SM. 
 In 2001 and updated in 2008, the WHO defined diag-
nostic criteria for mastocytosis and its various subtypes 
 [2, 3] . For SM, the so-called SM criteria are widely used 
( table 2 ). However, in a smaller cohort of patients, SM cri-
teria are not met and even if  KIT D816V is detectable and 
the patients are suffering from typical clinical mediator-
related symptoms a diagnosis of SM cannot be estab-
lished. For these patients, the preliminary term monoclo-
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 Abstract 
 Mast cell activation syndromes (MCAS) are clinically defined 
disease states with a largely unknown morphological back-
ground. Since mastocytosis may be associated with MCAS, it 
is crucial in every patient to document or exclude mastocy-
tosis by appropriate histological, molecular, and serological 
investigations of tissues/organs that are commonly involved 
in mastocytosis like skin, mucosa of the gastrointestinal tract 
and bone marrow. Accordingly, histopathological investiga-
tion including immunohistological stains is crucial to reach 
the final diagnosis in such patients and to classify MCAS into 
primary MCAS, which can present with or without evidence 
of overt mastocytosis, or secondary MCAS, where an under-
lying disease with or without tissue inflammation is detect-
ed. Cases without evidence of mastocytosis, monoclonal 
mast cells, or any underlying disease should be termed idio-
pathic MCAS. When the activating point mutant  KIT D816V is 
detectable but criteria for diagnosis of mastocytosis are not 
completely met, a so-called (mono)clonal MCAS as a subvari-
ant of primary MCAS should be diagnosed. 
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nal mast cell activation syndrome (mMCAS) has been 
proposed  [4, 5] . 
 So far, it remains unknown whether or not MCAS is 
a pre-phase of mastocytosis, and whether or not also oth-
er forms of severe anaphylaxis may be related to an ab-
normal mast cell activation or even mast cell monoclo-
nality  [6, 7] . To explore these possibilities and to define 
the impact of pathological staging and grading in these 
patients, a consensus conference was organized in 2010 
in Vienna, Austria. The general outcome of this confer-
ence has been presented in a separate publication. In the 
current article, the impact and value of appropriate his-
tological and immunohistochemical evaluation in pa-
tients with clinical signs of unexplained mast cell activa-
tion is highlighted, thereby underlining the crucial role 
of the pathologist for definitive subtyping of MCAS, 
which can be a primary condition with or without SN, a 
secondary MCAS, or idiopathic MCAS. It cannot be 
overemphasized that knowledge of all relevant clinical 
information is also of major importance to achieve a cor-
rect diagnosis in cases of suspected SM/MCAS ( table 3 ). 
Published algorithms based on clinical and serological 
data are available to facilitate a clinical prediction of SM 
or mMCAS  [8] .
 Evaluation of Tissues in Suspected MCAS 
 Evaluation of tissues commonly involved in mastocy-
tosis like bone marrow, skin and mucosa of the gastroin-
testinal tract is crucial for diagnosis and exact subtyping 
of MCAS. The routine histological approach focuses on 
detection of compact mast cell infiltrates in extracutane-
ous tissues as the main diagnostic criterion for SM. In 
order not to overlook small mast cell infiltrates, the use 
of immunohistochemical stains is strongly recommend-
ed in all cases of suspected MCAS/SM. Here, tryptase and 
CD117  (KIT) are the markers of choice for screening tis-
sue sections, allowing even very small mast cell infiltrates 
to be detected. Proof of expression of CD25 by mast cells 
demonstrates an aberrant immunophenotype and is de-
fined as a minor diagnostic criterion of SM. Since one 
major and at least one minor criterion are essential for a 
diagnosis of SM to be established, detection of small com-
pact mast cell infiltrates with expression of CD25 is suf-
ficient to definitively diagnose SM. 
 In patients in whom compact mast cell infiltrates are 
missing, it is of major importance to receive all clinical 
informations, especially on the presence or absence of 
skin lesions of urticaria pigmentosa-type, elevated se-
rum tryptase, hematological parameters, and anaphy-
lactic reactions but also on the presence of  KIT D816V, 
which is another minor diagnostic criterion for SM. In 
this regard, it is noteworthy that the presence of 3 minor 
SM criteria is also sufficient to establish a diagnosis of 
SM. Altogether, appropriate staging for SM should in-
clude a bone marrow biopsy specimen of at least 2 cm in 
length, because of the often very discrete infiltration, 
with only a few small compact mast cell infiltrates  [9] . 
Moreover, smears of blood and bone marrow must be 
evaluated to be able to subtype the SM properly. In addi-
tion, flow cytometry should be performed if the tech-
nique is available. In particular, flow cytometry is help-
ful in cases where mast cell numbers are low and mast 
cells do not form compact infiltrates in tissue sections 
(up to 20%) [own unpubl. obs.]. In such patients, flow 
Table 1. C lassification of mast cell disorders
1 Cutaneous mastocytosis (CM)
2 Indolent systemic mastocytosis (ISM)
a Smoldering systemic mastocytosis (SSM)
b Bone marrow mastocytosis (BMM)
c Well-differentiated ISM (WDISM)
3 Aggressive systemic mastocytosis (ASM)
4 SM-AHNMD*
5 Mast cell leukemia (MCL)
6 Mast cell sarcoma (MCS)
7 Extracutaneous (benign) mastocytoma
* Associated non-mast-cell clonal hematological disorder.
A primary MCAS can occur in any type of mast cell disorder.
Table 2. S ystemic mastocytosis: diagnostic criteria
Main criterion
Compact infiltrate in an extramedullary organ (>15 mast cells)
Minor criteria
Prominent spindling of mast cells (>25% in a compact infiltrate)
Aberrant immunophenotype of mast cells (CD2 and/or CD25)
Activating point mutation of c-kit at codon 816
(usually KIT D816V)
Elevated baseline serum tryptase (>20 ng/ml)
D iagnosis of systemic mastocytosis can be established when 
the major and at least 1 minor criterion or at least 3 minor criteria 
are fulfilled.
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cytometry can still reveal an abnormal mast cell immu-
nophenotype with co-expression of CD25, supporting 
the diagnosis SM. In a few patients with skin lesions of 
urticaria pigmentosa-type, staging might reveal absence 
of SM thus enabling a diagnosis of pure cutaneous mas-
tocytosis (‘real’ urticaria pigmentosa). In all the cases 
lacking compact mast cell infiltrates, CD25 expression 
by mast cells and  KIT D816V, mastocytosis can be ruled 
out definitively. Presence of round and strongly meta-
chromatic, loosely scattered mast cells is best interpreted 
as mast cell hyperplasia. However, there are no widely 
accepted criteria for normal or increased numbers of 
mast cells in various tissue sites  [10] . The interpretation 
of such findings therefore mainly depends on the experi-
ence of the pathologist. It should also be stated here that 
it is impossible to document mast cell activation in tissue 
sections, unless extensive degranulation with presence 
of hypogranulated or even degranulated mast cells in 
large numbers is seen. Finally, it is crucial for the pathol-
ogist to be aware of the fact that the evaluation of aber-
rant marker expression in mast cells may be tricky pend-
ing on the organ and tissue sites examined. 
 Since bone marrow trephine biopsy specimens have 
been shown to be the main goal for confirmation or ex-
clusion of SM in patients with MCAS a list of the main 
findings and corresponding diagnoses is given in the fol-
lowing  [11] :
 (1) Multifocal compact mast cell infiltrates: SM (mainly 
indolent SM or so-called bone marrow mastocytosis, 
very rarely aggressive or leukemic SM, compatible 
with primary MCAS). 
 (2) Increase in loosely scattered spindle-shaped mast cells 
with CD25 expression,  KIT D816V mutation and 
chronically elevated serum tryptase but compact tis-
sue infiltrates are lacking: SM (mainly indolent or oc-
cult SM but also so-called bone marrow mastocytosis, 
compatible with primary MCAS). 
 (3) Increase in loosely scattered spindle-shaped mast cells 
with  KIT D816V +/– CD25 but without elevated serum 
tryptase: primary monoclonal MCAS. 
 (4) Increase in loosely scattered round mast cells lacking 
CD25 and  KIT D816V: mast cell hyperplasia (compat-
ible with secondary or idiopathic MCAS). 
 In contrast to the bone marrow, interpretation of 
immunohistochemical findings in the gastro-intestinal 
tract mucosa may be very difficult due to both the often 
very strong background staining of anti-tryptase and ob-
vious cross-reactivity of cells in the lamina propria mu-
cosae that are definitively no mast cells. Moreover, there 
are often many CD25-expressing lymphoid and histio-
cytic cells making the assessment of CD25 expression by 
loosely scattered mast cells sometimes very difficult. It 
should be emphasized here that CD25 immunohisto-
chemistry is easy to interprete in the bone marrow due 
to the virtual lack of CD25-expressing lymphocytes and 
histiocytes but clear-cut reactivity of megakaryocytes 
(serving as internal control) which are easily distin-
guishable from mast cells. However, finding of an in-
tramucosal spindle-shaped cell with expression of CD25 
can be interpreted as atypical mast cell. Of course, in the 
rare presence of compact often band-like mast cell infil-
trates CD25 expression is far more easily to assess (or 
exclude). The marker of choice for screening of cases of 
suspected SM/MCAS is anti-CD117  (KIT) which pro-
duces a clear staining picture with some loosely scattered 
mast cells even in normal or inflamed mucosa. The rare 
occurrence of mast cells in an intra-epithelial position 
does not allow any conclusions to be drawn about its 
state, reactive and neoplastic, but is overall more fre-
quently observed in states of marked mast cell hyperpla-
sia and mastocytosis.
 In the normal/reactive liver mast cells are virtually 
absent from the sinusoids but loosely distributed mast 
cells can be commonly found within portal triads espe-
Table 3. E ssential information for the hematopathologist in cases 
with suspected MCAS or SM*
Typical skin lesions of urticaria pigmentosa
KIT mutation status, especially KIT D816V
Male sex**
Baseline serum tryptase at the time of biopsy
(especially when >25 g/l**)
Baseline serum tryptase variations over time
Additional increase of tryptase during an attack
Allergy/anaphylaxy
Presyncopal and/or syncopal episodes**
Serum IgE
Chronic inflammatory disorders
Absence of urticaria and angioedema**
Hepatosplenomegaly
Lymphadenopathy





* Or what the hematopathologist should ask for (depending on 
the clinical situation).
** According to Alvarez-Twose et al. [8].
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cially in chronic inflammation (‘hepatitis’) or fibrosis/
cirrhosis. Presence of intrasinusoidally located mast cells 
is highly suggestive of mastocytosis. Expression of CD25 
by mast cells is relatively easily assessable in this tissue 
site. Compact mast cell aggregates are rare and more of-
ten observed in the triads than in the sinusoids. Analysis 
of liver trephine specimens may sometimes be necessary 
in patients with aggressive or leukemic SM showing 
marked hepatomegaly but involvement of the liver is, al-
though rarely confirmed, also seen in patients with in-
dolent SM.
 Marked splenomegaly and lymphadenopathy are 
common findings in patients with aggressive or leukemic 
SM but are rarely present in indolent SM. Thus, in the 
spleen and in lymph nodes, diagnosis of SM rarely has to 
be initially confirmed. Due to the high amount of CD25 
expression by lymphocytes and histiocytes in both tissue 
sites difficulties may arise when immunohistochemical 
findings have to be interpreted to determine an aberrant 
immunophenotype of mast cells. In the majority of cases, 
however, multifocal compact mast cell infiltrates enable 
a diagnosis of tissue involvement by SM to be established 
at first glance. 
 Depending on the demonstration or exclusion of mas-
tocytosis and the presence or absence of monoclonal mast 
cells by appropriate histological immunohistochemical 
investigation of tissue samples, the following preliminary 
classification of MCAS is proposed:
 (1) Cutaneous mastocytosis with primary MCAS. 
 (2) Systemic mastocytosis with primary MCAS. 
 (3) Primary MCAS with  KIT -mutated clonal mast cells, 
but only 2 minor SM criteria: (mono)clonal MCAS 
(mMCAS). 
 (4) Secondary and idiopathic MCAS (with and without 
reactive mast cell hyperplasia or signs of tissue inflam-
mation). 
 In other words, a primary MCAS can develop in any 
subtype of mastocytosis and even in the absence of mas-
tocytosis, i.e. when clonal mast cells are detectable but 
the criteria for SM are not (yet) fulfilled (monoclonal 
MCAS)  [13] . 
 Conclusions 
 It is strongly recommended that in all patients with 
MCAS mastocytosis has to be confirmed or excluded. In 
cases with cutaneous disease and macroscopically typical 
efflorescenses a diagnosis of secondary MCAS can be es-
tablished almost clinically. In all other patients SM has to 
be proven (or excluded) by histological investigation of a 
bone marrow biopsy specimen including immunohisto-
chemical studies (tryptase, CD117 and CD25). In addi-
tion, molecular analysis should be done in all cases, in 
order to detect or exclude the presence of the activating 
point mutation  KIT  D816V  [12] . Other extracutaneous 
tissues can also be evaluated in this respect, the mucosa 
of the gastrointestinal tract being of major diagnostic 
importance. In contrast to the almost standardized ap-
proach in the bone marrow diagnosis of mastocytosis 
with involvement of the mucosa may pose more problems 
for the pathologist due to several reasons: (1) general pa-
thologists investigating mucosa commonly are less famil-
iar with mastocytosis than hematopathologists; (2) non-
specific staining with antibodies against tryptase and/or 
CD25 may lead to false-positive diagnoses (which is not 
the case in the bone marrow due to virtual absence of 
CD25-expressing lymphoid cells), and (3) compact diag-
nostic infiltrates are rarely detectable and most diagnoses 
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